Baxter International

Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences

Short Interest In Abbott Labs And Baxter International Doubles

Short Interest In Baxter International And Celator Pharmaceuticals Doubles

Short Interest In Abbott Labs And Baxter International Doubles

Short Interest In Baxter International And Celator Pharmaceuticals Doubles

Big Biotech In The Earnings Spotlight

Mixed Earnings Expectations For Merck And Pfizer

Big Biotech In The Earnings Spotlight

Mixed Earnings Expectations For Merck And Pfizer

Market Wrap For March 27: Markets Lower Following Mixed Economic Data

Market Wrap For March 17: Investors Focused On Economic Data Instead Of Crimea Concerns

Baxter International Recent News

Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR)

Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)

Top Performing Dividend Payers in Health Care with the Most Upside Potential (TRIB, STE, CMN)

St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now

Caterpillar, Discover Financial and Other Illinois Primary Stock Picks

Top Performing Health Care Stocks in January

UPDATE: Morgan Stanley Raises PT on Baxter International from $58 to $63

Piper Jaffray Comments on May Data for Baxter International

Goldman Sachs PT Changes For 5/31

Morgan Keegan Raises PT On Baxter Int'l To $70

Bank of America Raises PT on Baxter International To $67

Piper Jaffray Reiterates Overweight Rating On BAX

Piper Jaffray Comments On Baxter Q1 Results

Piper Jaffray Maintains OW Rating On BAX

J.P. Morgan Comments On Baxter Presentations At AAAAI

Morgan Keegan Comments On FDA Safety Alert On CSL's Vivaglobin For Baxter International

Piper Remains Overweight On Baxter

Morgan Keegan Responds To Investor Questions Regarding BAX Sigma Pump

There's Still Upside Left For Baxter International, Deutsche Bank Reports

JP Morgan Updates Model On BAX

Morgan Keegan Reiterates Outperform On BAX

Baxter's Growth Sustainable Through 2013/2014 According To Goldman